Lipids & metabolic liver disease
Inclisiran versus alirocumab in improving lipid profile parameters: A systematic review and meta‐analysis
Authors' conclusion
Alirocumab was superior to inclisiran in improving the lipid profile, especially in reducing LDL-C, total cholesterol and triglycerides.
Study context
- Population
- Patients in clinical trials evaluating the lipid profile (dyslipidemia)
- Participants
- 30,718 patients32 studies
- Comparison
- Alirocumab vs inclisiran
- Outcome
- Change in lipid profile parameters from baseline
- Follow-up
- 12 and 24 weeks
Methodological detailsPRISMA, Databases searched 2 July 2024: PubMed, Scopus, Web of Science
- PRISMA
- Databases searched 2 July 2024: PubMed, Scopus, Web of Science
Pooled result
As reported in the abstract
Low-density lipoprotein cholesterol (LDL-C) reduction · 24 weeks
Alirocumab 75 mg
−51.54%
95% CI −53.43%–-49.66%
Inclisiran 300 mg
−41.34%
95% CI −50.30%–-31.34%
P = 0.05
Further pooled results
| Outcome | Alirocumab 75 mg | Alirocumab 150 mg | Inclisiran 300 mg | P value |
|---|---|---|---|---|
| Lipoprotein(a) reductionAlirocumab 75 mg vs Inclisiran 300 mg · no statistically significant difference | −22.35% (95% CI −24.67–-20.03) | −25.17% (95% CI −30.94–-19.41) | −13.37 (95% CI −28.66–1.93) | P = 0.26 |
| Lipoprotein(a) reductionAlirocumab 150 mg vs Inclisiran 300 mg · no statistically significant difference | P = 0.16 |
- Total cholesterol reduction, alirocumab 75 mg vs inclisiran 200 and 300 mg · 24 weeks · favouring alirocumab 75 mg
- P < 0.01
- Total cholesterol reduction, alirocumab 75 mg vs inclisiran 200 and 300 mg · 24 weeks · favouring alirocumab 75 mg
- P < 0.01
- TG reduction, alirocumab 75 mg vs inclisiran 200 and 300 mg · 24 weeks · favouring alirocumab 75 mg
- P = 0.02
- TG reduction, alirocumab 75 mg vs inclisiran 200 and 300 mg · 24 weeks · favouring alirocumab 75 mg
- P = 0.04
- Total cholesterol reduction, alirocumab 150 mg vs both inclisiran doses · alirocumab 150 mg superior
- P < 0.01
- Total cholesterol reduction, alirocumab 150 mg vs both inclisiran doses · alirocumab 150 mg superior
- P < 0.01
Original publication
Inclisiran versus alirocumab in improving lipid profile parameters: A systematic review and meta‐analysis. Diabetes Obes Metab. Published 25 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →